HB 347 makes a broad set of amendments to Utah’s social services and behavioral health statutes. It revises the Medicaid ACA Fund to clarify permitted revenue sources and uses, including hospital assessments, intergovernmental transfers, sales tax revenue, and legislative appropriations, while removing a prior reference to savings from psychotropic drugs on the preferred drug list. The bill also updates definitions and licensing provisions in the human services code, including new rules for adult substance use and mental health providers operating as “deemed sites” based on accreditation and compliance history.
A major policy change in the bill is the creation of a framework allowing certain adult substance use and mental health treatment sites to be exempt from routine on-site renewal inspections if they are nationally accredited, in good standing, and meet reporting requirements. The bill also changes Medicaid drug policy by renaming and narrowing the preferred drug list provisions around atypical anti-psychotic drugs, while preserving protections for immunosuppressive drugs and adding a requirement that Medicaid cover certain nonpreferred psychotropic drugs when a patient has failed a preferred alternative or is already stabilized on the medication. It also expands the Medicaid waiver for qualified inmates reentering the community to include certified community health worker services, and makes related updates to case management, advisory committee membership, and criminal justice reporting statutes.
The bill includes a $1.1 million General Fund appropriation for fiscal year 2026, with targeted funding for homeless medical respite/end-of-life care, a behavioral health grant to Valley Behavioral Health in Tooele County, and services through Odyssey House for people exiting inpatient treatment, jail, or unstable housing. It also directs funding toward skilled nursing facility behavioral health services. These appropriations indicate that the bill is not only regulatory but also programmatic, supporting specific service expansions within the state’s health and human services system.
Overall, the sentiment around HB 347 appears strongly favorable and noncontroversial. The bill passed the House committee, House floor, Senate committee, Senate floor, and House concurrence unanimously, with no recorded dissenting votes. There were no committee transcript snippets provided, but the voting history suggests broad bipartisan support and little visible opposition.
The main points of potential contention, based on the text itself, are the shift toward accreditation-based oversight for adult behavioral health providers and the Medicaid preferred drug list changes for atypical anti-psychotic and other psychotropic medications. Those provisions affect treatment providers, Medicaid enrollees, prescribers, and the department’s inspection and prior-authorization processes. However, the unanimous votes suggest that any concerns were either resolved in substitute/amended form or were not significant enough to generate recorded opposition.
HB 347 amends multiple sections of Utah Code affecting Medicaid financing, behavioral health licensing, correctional reentry health coverage, case management certification, first responder mental health resources, and criminal justice reporting. It creates a new statutory pathway for certain adult substance use and mental health treatment sites to be treated as deemed sites based on accreditation and compliance, and it changes Medicaid drug coverage rules to preserve access to certain psychotropic medications under specified conditions. The bill also adds certified community health worker services to the limited Medicaid benefit for qualified inmates and makes conforming changes to advisory and reporting structures across health and justice agencies. In addition, it appropriates $1.1 million in General Fund money for FY 2026 to support homeless services and behavioral health programs.
The bill’s legislative history shows unanimous support at every recorded stage, including committee recommendations and floor passage in both chambers, followed by House concurrence with Senate amendments. That voting pattern indicates a broadly positive sentiment toward the bill and suggests it was viewed as a practical package of health and human services updates rather than a controversial policy measure. The absence of recorded dissent or committee testimony in the provided materials further suggests limited public or legislative opposition.
The most notable policy issues are the bill’s changes to behavioral health licensing oversight and Medicaid drug management. Providers may view the deemed-site provision as a regulatory relief measure, while others could be concerned about reduced routine inspection frequency and reliance on private accreditation. The Medicaid preferred drug list changes, especially those involving atypical anti-psychotic and other psychotropic drugs, could also draw concern from prescribers, advocates, or payers because they affect prior authorization, formulary management, and continuity of care. Even so, the unanimous votes imply these issues did not produce significant visible conflict during the legislative process.